Calls for proposals
Search
Calls for proposals
DigestScience funds cutting-edge research programmes on themes in digestive tract disease and human nutrition. The calls for proposals are issued by a high-level Scientific Advisory Board. To receive information on all our calls for proposals, do not hesitate to sign up to the DigestScience newsletter.
Call for project
2011
Subject
DigestScience Foundation requests initial expressions of interest for invitation to submit full grant applications for funding to support research projects investigating ground-breaking areas relevant to: “Manipulation of intestinal flora in health and disease : areas of interest include genetically selected/modified organisms, virus, phages, parasites, novel prebiotics…That will help patients with intestinal diseases."Up to €500.000 for 2 years may be requested to support currently unfunded projects.
The Winner
The project : "Bacteriophages and Bacteria Relationships in intestinal flora" ; Coordinator: L. Debarbieux, Institut Pasteur, Paris.
2009
Subject
Digest Science Foundation requested initial expressions of interest for invitation to submit full grant applications for funding to support research projects investigating ground-breaking areas relevant to immune-mediated intestinal disorders.
Up to €1m for 2 years requested to support currently unfunded projects.
Areas of interest include inflammatory bowel disease, celiac disease and immunological or inflammatory aspects of irritable bowel syndrome.
Review process performed by the scientific committee of Digest Science together with selected world authorities.
The Winner
Prof D.W. Hommes, Head of the department of hepato-gastroenterology of the University of Leiden (Netherlands), was selected for his project "Mesenchymal Stromal Cell Therapy for Crohn' S Disease", among the 25 European laboratories which had submitted a research project. Evaluated by 2 international experts in this field of research, he was elected by our Scientific Council.
This project on cellular therapy in Crohn's disease will be led by Dutch and Irish teams. It is an innovating and original therapeutic approach of which we can hope for fast opening on clinical trials with, as medium-term objective, a significant benefit for the patients.
- First results published in GUT, reference :
Duijjvestein M, Vos ACW, Roelofs H et al.GUT (2010).doi 10.1136/gut.2010.215152
Peut-on arrêter un traitement par Anti-TNF ?
Une étude prospective récente effectuée par le GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif) appelée Stori
Your employer appreciates your treatment !
The effect of adalimumab upon work productivity